The study is aimed at measuring serum concentrations of the anti-TB drug INH early during treatment and to establish a correlation between polymorphism in NAT2 and CYP2E1 genes with well documented roles in INH metabolism, hepatotoxicity, and clinical outcomes with GSTM1 variants. This evidence concerns the gene NAT2 and tuberculosis.